Company intelligence / Profile preview

resTORbio

Boston, Massachusetts, United Statesinvestor.adicetbio.com ↗

Ownership: Private
Employees: ~65
Development stage: Clinical

Overview

resTORbio's lead program RTB101, a TORC1 inhibitor, demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging. However, a Phase 3 trial in clinically symptomatic respiratory illness failed in November 2019, causing significant stock price decline[6].

Therapeutic areas: OtherNeurologyInfectious Diseases
Modalities: small molecules
Industry: Biotech

Drug pipeline

2 assets

RTB101

Clinical

Indications: Aging-related diseases, COVID-19

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on resTORbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on resTORbio.

Explore the full profile